Hans Arne M.
- Country
- Norway
- Department
- Nordlandssykehuset HF
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Trial of Elecoglipron (AZD5004) on Renal Decline and Mortality in Adults with Chronic Kidney Disease
- Evaluation of Zibotentan and Dapagliflozin Combination Versus Dapagliflozin Monotherapy in Chronic Kidney Disease with High Proteinuria: A Phase III Randomized Study
Data & Insights
Has run more than one trial at 22 of 261 partner sites.
Specializations
Nephrology Focus
The investigator specializes in advancing treatments for chronic kidney disease, with particular attention to patients experiencing high proteinuria. Their research encompasses innovative therapeutic approaches in nephrology.
- Renal Disease Management
- Proteinuria Treatment
- Kidney Function Preservation
Their expertise extends to investigating combination therapies for improved renal outcomes.
Therapeutic Innovation
The investigator's work centers on evaluating novel therapeutic combinations, including endothelin receptor antagonists and SGLT2 inhibitors in renal medicine. Their research aims to identify more effective treatment strategies.
- Combined Drug Therapy
- Renal Protection Strategies
- Treatment Efficacy Assessment
Their focus includes evaluating therapeutic tolerability and safety profiles in kidney disease treatment.
Clinical Outcomes
The investigator's research emphasizes measuring and improving kidney function progression through clinical intervention. They focus on developing strategies to slow renal function decline.
- Disease Progression Monitoring
- Treatment Response Assessment
- Long-term Outcome Evaluation
Their work includes comprehensive assessment of therapeutic interventions in kidney disease management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.